1999-2013年髋部骨折后二级骨折预防的地理差异:一项英国研究
该英国研究利用初级保健数据(Clinical Practice Research Datalink)分析1999-2013年髋部骨折前后抗骨质疏松药物处方的地理差异。骨折后0-4个月内处方率从1999年的5%升至2011年的51%,2013年降至39%。调整性别、年龄和BMI后地理差异仍存在,若所有患者按最高处方率地区治疗,全国每年可额外增加3214例患者起始治疗。
要点
- 髋部骨折前6个月内仅11%患者有抗骨质疏松药物处方。
- 骨折后0-4个月处方率1999年5%、2011年51%、2013年39%。
- 调整混杂因素后地理差异仍显著,随访5年持续存在。
核心结论
- 调整潜在混杂因素后,髋部骨折后抗骨质疏松药物处方仍存在显著地理差异。
- 需进一步研究医疗保健提供差异,可能有助于制定改善髋部骨折后二级骨折预防的策略。
研究设计与样本
- 利用初级保健数据库(Clinical Practice Research Datalink)识别1999-2013年间髋部骨折患者,分析骨折前及骨折后最长5年的抗骨质疏松药物处方。
- 分析口服双膦酸盐通用名药物可及前后处方地理差异,多因素logistic回归模型调整性别、年龄和体重指数(BMI)。
主要发现
- 髋部骨折前6个月内,11%患者有任何抗骨质疏松药物处方。
- 骨折后0-4个月内,抗骨质疏松药物处方率1999年为5%,2011年升至51%,2013年降至39%。
- 治疗启动的独立预测因素包括性别(男性OR 0.42,95%CI 0.36-0.49)、BMI(每增加1 kg/m2 OR 0.98,95%CI 0.97-1.00)和地理区域(东北地区 vs 中南地区:OR 1.29,95%CI 0.89-1.87 vs OR 0.56,95%CI 0.43-0.73)。
- 处方地理差异在5年随访期间持续存在。
- 若所有患者按最高处方率地区治疗,全国每年将额外有3214例髋部骨折患者起始治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究医疗保健提供差异,可能有助于制定改善髋部骨折后二级骨折预防的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Fragility fractures of the hip have a major impact on the lives of patients and their families. This study highlights significant geographical variation in secondary fracture prevention with even the highest performing regions failing the majority of patients despite robust evidence supporting the benefits of diagnosis and treatment. INTRODUCTION: The purpose of the study is to describe the geographic variation in anti-osteoporosis drug therapy prescriptions before and after a hip fracture during 1999-2013 in the UK. METHODS: We used primary care data (Clinical Practice Research Datalink) to identify patients with a hip fracture and primary care prescriptions of any anti-osteoporosis drugs prior to the index hip fracture and up to 5 years after. Geographic variations in prescribing before and after availability of generic oral bisphosphonates were analysed. Multivariable logistic regression models were adjusted for gender, age and body mass index (BMI). RESULTS: Thirteen thousand sixty-nine patients (76 % female) diagnosed with a hip fracture during 1999-2013 were identified. Eleven per cent had any anti-osteoporosis drug prescription in the 6 months prior to the index hip fracture. In the 0-4 months following a hip fracture, 5 % of patients were prescribed anti-osteoporosis drugs in 1999, increasing to 51 % in 2011 and then decreasing to 39 % in 2013. The independent predictors (OR (95 % CI)) of treatment initiation included gender (male 0.42 (0.36-0.49)), BMI (0.98 per kg/m2 increase (0.97-1.00)) and geographic region (1.29 (0.89-1.87) North East vs. 0.56 (0.43-0.73) South Central region). Geographic differences in prescribing persisted over the 5-year follow-up. If all patients were treated at the rate of the highest performing region, then nationally, an additional 3214 hip fracture patients would be initiated on therapy every year. CONCLUSIONS: Significant geographic differences exist in prescribing of anti-osteoporosis drugs after hip fracture despite adjustment for potential confounders. Further work examining differences in health care provision may inform strategies to improve secondary fracture prevention after hip fracture.
引用
- Shah A, Prieto-Alhambra D, Hawley S, et al. Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study. Osteoporos Int. 2016. PMID: 27812809. doi:10.1007/s00198-016-3811-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。